A New Class of Therapies

for serious degenerative disorders caused by nucleotide repeat expansions, including Friedreich’s ataxia

LEARN MORE From OUR PRESS RELEASE

Founding TEAM

Pratik Shah, PhD

Co-founder &
Executive Chairman

Pratik Shah, Ph.D., is a co-founder and executive chairman of Design Therapeutics. In addition, Dr. Shah serves as chairman of the board at ARS Pharmaceuticals. Until February of 2020, he served as chairman of Synthorx, Inc., a biotechnology company developing innovative protein therapeutics for cancer and autoimmune disorders that was acquired by Sanofi for $2.5 billion. Before that, Dr. Shah was president and chief executive officer of Auspex Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel medicines for people with movement disorders, including AUSTEDO® (deutetrabenazine). He became involved in Auspex as an investor in 2007 and served as its chairman until he took over as its chief executive officer in 2013, after which he took the company public and oversaw its growth until its acquisition by Teva Pharmaceuticals for $3.5 billion in 2015. Before that, Dr. Shah was a partner in the healthcare venture capital firm Thomas, McNerney & Partners for nearly a decade, and prior to that, he co-founded two biotechnology companies and was also a consultant at McKinsey & Company in San Francisco. Dr. Shah obtained his Ph.D. in biochemistry and molecular biology as well as his MBA in finance from the University of Chicago.

Aseem Ansari, PhD

Co-founder
& Director

Aseem Z. Ansari, Ph.D., is a co-founder of Design Therapeutics and serves as a director on the company’s board of directors. Dr. Ansari is an internationally recognized scientist who has effectively blended rigorous training in chemistry with deep experience in experimental biology. Dr. Ansari is the chair of the Department of Chemical Biology and Therapeutics at St. Jude Children’s Research Hospital. From 2002 to 2019, Dr. Ansari was a faculty member at the University of Wisconsin and during this time he performed the foundational research that led to Design Therapeutics. Dr. Ansari is also a founder of Winstep Forward, a US education non-profit organization. He received his Ph.D. in biochemistry and chemistry from Northwestern University and completed postdoctoral training at Harvard. Dr. Ansari’s research has produced important new insights into the cellular processes that govern gene expression and has developed novel small molecules that can influence gene regulatory networks and cell fate.

Sean Jeffries, PhD

Chief Business Officer

Sean Jeffries, Ph.D., is the chief business officer at Design Therapeutics. Dr. Jeffries brings over twenty years of experience in biopharma with extensive experience in strategy and R&D. Prior to Design, Dr. Jeffries led projects to develop R&D and therapeutic strategies for biopharma at the Boston Consulting Group. He was instrumental in pioneering miniPCR, which performed the first PCR on the international space station. Prior to that, Dr. Jeffries established and led the informatics group at Kalypsys. Dr. Jeffries completed his Ph.D. at the University of Cambridge in epigenetics as an NIH-Cambridge scholar.

Board of Directors

Pratik Shah, PhD

Co-founder &
Executive Chairman

Pratik Shah, Ph.D., is a co-founder and executive chairman of Design Therapeutics. In addition, Dr. Shah serves as chairman of the board at ARS Pharmaceuticals. Until February of 2020, he served as chairman of Synthorx, Inc., a biotechnology company developing innovative protein therapeutics for cancer and autoimmune disorders that was acquired by Sanofi for $2.5 billion. Before that, Dr. Shah was president and chief executive officer of Auspex Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel medicines for people with movement disorders, including AUSTEDO® (deutetrabenazine). He became involved in Auspex as an investor in 2007 and served as its chairman until he took over as its chief executive officer in 2013, after which he took the company public and oversaw its growth until its acquisition by Teva Pharmaceuticals for $3.5 billion in 2015. Before that, Dr. Shah was a partner in the healthcare venture capital firm Thomas, McNerney & Partners for nearly a decade, and prior to that, he co-founded two biotechnology companies and was also a consultant at McKinsey & Company in San Francisco. Dr. Shah obtained his Ph.D. in biochemistry and molecular biology as well as his MBA in finance from the University of Chicago.

Aseem Ansari, PhD

Co-founder
& Director

Aseem Z. Ansari, Ph.D., is a co-founder of Design Therapeutics and serves as a director on the company’s board of directors. Dr. Ansari is an internationally recognized scientist who has effectively blended rigorous training in chemistry with deep experience in experimental biology. Dr. Ansari is the chair of the Department of Chemical Biology and Therapeutics at St. Jude Children’s Research Hospital. From 2002 to 2019, Dr. Ansari was a faculty member at the University of Wisconsin and, during this time, he performed the foundational research that led to Design Therapeutics. Dr. Ansari is also a founder of Winstep Forward, a US education non-profit organization. He received his Ph.D. in biochemistry and chemistry from Northwestern University and completed postdoctoral training at Harvard. Dr. Ansari’s research has produced important new insights into the cellular processes that govern gene expression and has developed novel small molecules that can influence gene regulatory networks and cell fate.

Simeon George, MD

Director

Dr. George is CEO of S.R. One. He was formerly a consultant at Bain and Co. and an associate in the healthcare investment banking group at Goldman Sachs. Dr. George is a co-founder and board member of Nkarta and also currently serves on the boards of Bird Rock Bio, CRISPR Therapeutics (CRSP), eFFECTOR Therapeutics, Principia Biopharma (PRNB) and Turning Point Therapeutics (TPTX). He previously served of the boards of Progyny (PGNY), HTG Molecular (HTGM), Genocea Biosciences (GNCA) and Semprus (acquired by Teleflex). Dr. George received a B.A. in neuroscience from Johns Hopkins University, where he graduated Phi Beta Kappa. He received an M.D. from the University of Pennsylvania School of Medicine and a MBA (Mayer Scholar) from the Wharton School at the University of Pennsylvania.

Rodney Lappe, PhD

Director

Rodney Lappe, Ph.D., has had a distinguished career as a biopharmaceutical scientist and executive. Most recently, Dr. Lappe served as executive chairman of the board of directors for Mirati Therapeutics, a role he had served as June 2016 (after becoming a member of the board in June 2012 and chairman of the board in July 2013). During this time, Dr. Lappe also served as the senior vice president of Tavistock Life Sciences, a private investment firm. Previously, Dr. Lappe was group senior vice president, Pfizer Worldwide Research and Development and chief scientific officer for CovX in San Diego. Dr. Lappe has also served as vice president for cardiovascular and metabolic diseases at Pharmacia where he was also site leader for Pharmacia in St. Louis. Prior to joining Pharmacia, he held positions with Wyeth, Rorer Central Research, CIBA Geigy and Searle Pharmaceuticals. Dr. Lappe received his B.A. from Blackburn College and his Ph.D. in pharmacology from Indiana University.

Stella Xu, PhD

Director

Dr. Stella Xu is managing director of Quan Capital, a life science venture fund with deep expertise and broad experiences in cross-border value creation and global investments. Prior to Quan, Stella was corporate vice president/site head of Roche R&D Center China and a core member of the global management team of Roche’s Immunology, Inflammation & Infectious Diseases Division. From 2012 to 2017, she led the fully integrated team of approximately 200 scientists to deliver an innovative pipeline from discovery to global clinical development. She also had extensive global business development experience with Roche Partnering. Stella joined Roche from McKinsey US and worked in biotech R&D earlier in her career. Stella received her Ph.D. in immunology from Northwestern University and B.S. in biophysics from Peking University. Stella currently serves on the board of NextCure (Nasdaq: NXTC), Centrexion Therapeutics, Tempest Therapeutics, Walking Fish Therapeutics and Zidan Medical. She was also previously a board member of ARMO BioSciences (Nasdaq: ARMO).

Pratik Shah, PhD

executive chairman & co-founder

Aseem Ansari, PhD

Board Member, co-founder, & director